Translocation Renal Cell Carcinoma, from the CureRays guide library.

Translocation renal cell carcinoma is a distinct kidney cancer driven by a TFE3 or TFEB gene fusion that tends to affect younger people, can spread to lymph nodes early, and is treated mainly with surgery plus modern targeted and immune therapies.

What it is.

Most kidney cancers occur in older adults, but translocation renal cell carcinoma stands apart: it is part of the 'MiT family' of kidney cancers and is the most common kidney cancer in children and young adults, though it occurs at any age. It is defined by a specific genetic event — a translocation, where a piece of one chromosome breaks off and fuses to another, switching on the TFE3 gene (on the X chromosome) or, less often, the TFEB gene. This fusion acts as the master driver of the cancer. Some cases follow earlier chemotherapy in childhood. These tumors can look like ordinary clear cell or papillary kidney cancer, so molecular testing (a TFE3 or TFEB stain or fusion test) is needed to recognize them. They are notable for reaching the lymph nodes relatively early even when the kidney tumor is small, and for sometimes recurring many years — even decades — after surgery, which makes long-term follow-up important.

How radiation treats it.

Radiation damages the DNA inside cancer cells so they can no longer divide, while nearby normal tissue repairs itself. Kidney cancers were long thought to resist radiation, but modern high-dose, highly focused techniques like SBRT overcome that resistance by delivering ablative doses with pinpoint accuracy. In translocation RCC, radiation is used to control the primary tumor when surgery isn't possible, to treat individual metastases, and to relieve symptoms. It is delivered as a few short, painless sessions and leaves no radioactivity in your body, so you stay safe to be around others throughout.

The ways we can treat it.

Stereotactic body radiation therapy (SBRT). Very precise, high-dose beams from many angles ablate the primary tumor in patients who can't have surgery, or treat individual metastases in bone, lung, or other sites in a few sessions.

Palliative radiation. Shorter courses of focused radiation relieve pain or other symptoms from bone or other metastases, improving quality of life.

Image-guided radiation (IGRT). Daily imaging lets the team target moving kidney and abdominal tumors accurately while sparing the bowel, liver, and the opposite kidney.

Questions we hear often.

I'm young — why did I get kidney cancer? Translocation renal cell carcinoma is one of the few kidney cancers that commonly affects children and young adults. It's caused by a gene fusion (involving TFE3 or TFEB) that switches on the cancer — not by lifestyle — and in some cases follows chemotherapy given for an earlier childhood illness.

Why is molecular testing of my tumor important? Under the microscope these tumors can look like ordinary kidney cancers, but they behave differently and respond to specific therapies. A TFE3/TFEB stain or fusion test confirms the diagnosis so you get the right treatment and the right follow-up plan.

Why do I need follow-up for so many years? This cancer can come back a very long time after surgery — sometimes decades later. Long-term scans let your team detect any recurrence early, when it can often be treated effectively with surgery, targeted therapy, immunotherapy, or focused radiation.

This guide is informational only. It is not medical advice — please confirm anything here with your care team.